The consumer genome sequencing company 23andMe is a sinking ship – and its CEO is conducting the orchestra. As Wired reports, 23andMe CEO Anne Wojcicki was chipper on a February 7 earnings call despite the company's abysmal revenue report that led to its stock being devalued to below 75 cents per share, down a whopping 93 percent from the $16.04 when it first went public. "We are an unusual company," Wojcicki said, per Wired, during the investor call. That response very much undersells the circumstances that may lead to 23andMe spinning off its consumer DNA testing and therapeutics wings into...